Although the new generation of antithrombotic drugs
provides marked improvements over warfarin, they all
still carry bleeding risk. S100
calcium binding protein A9 could represent a new target that,
when blocked, prevents thrombosis without increasing that risk.1
Mitjans said that the study raises the question of
whether other members of the S100 family of proteins-some of which have been
implicated in atherosclerosis5 and cardiac fibrosis6-might also be involved
in thrombotic processes.
A significant gap in the JCI study was that the
team only tested the antithrombotic effects of S100a9 knockout-not an
actual S100A9 inhibitor-in the mouse models.
M.J. SciBX 7(21);
Published online May 29, 2014
1. Wang, Y. et al. J.
Clin. Invest.; published online April 1, 2014; doi:10.1172/JCI70966
Contact: Daniel I. Simon, University Hospitals Case Medical Center,
2. Healy, A.M. et al.
Circulation 113, 2278-2284 (2006)
3. Morrow, D.A. et al.
Am. Heart J. 155, 49-55 (2008)
4. Croce, K. et al.
Circulation 120, 427-436 (2009)
5. Basta, G. Atherosclerosis
196, 9-21 (2008)
6. Tamaki, Y. et al. J.
Mol. Cell. Cardiol. 57, 72-81 (2013)
Active Biotech AB SSE:ACTI),
Brigham and Women's Hospital, Boston, Mass.
Cancer Research UK, London, U.K.
Case Western Reserve University, Cleveland, Ohio
Case Western Reserve University School of Medicine, Cleveland, Ohio
Harvard Medical School, Boston, Mass.
InflammatoRx Inc., Quebec City, Quebec, Canada
Ipsen Group (Euronext:IPN; Pink:IPSEY),
Research Institute, London, U.K.
Lykera Biomed S.A., Barcelona, Spain
Medical College of Wisconsin, Milwaukee, Wis.
Portola Pharmaceuticals Inc. (NASDAQ:PTLA), South San
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva,
University Hospitals Case Medical Center, Cleveland, Ohio
University of Michigan, Ann Arbor, Mich.